Abstract
AimsAlthough preliminary studies have demonstrated safety and effectiveness of single replacement therapy for growth hormone deficiency or testosterone deficiency in heart failure (HF), no data are available regarding the combined treatment with both GH and T in this setting. Thus, the aim of the present hypothesis generating pilot study was to evaluate the effectiveness and safety of multiple hormonal replacement therapies in chronic HF.Methods and resultsFive stable HF with reduced ejection fraction patients, with a concomitant diagnosis of growth hormone deficiency and testosterone deficiency, on top of guideline‐based HF treatment underwent 1 year of GH replacement therapy by subcutaneous injections of somatotropin at a dose of 0.012 mg/kg every second day. After 12 months, a T replacement treatment was added at a dosage of 1000 mg every 3 months. Each patient underwent a complete M‐mode, two‐dimensional, and Doppler echocardiographic examination, and an incremental symptom‐limited cardiopulmonary exercise test on a bicycle ergometer at baseline (BL), after 1 year of GH treatment (V1), and after 1 year of combined GH + T treatments (V2). One‐year of GH treatment resulted in a significant improvement in left ventricular ejection fraction (+5.4%, P < 0.01), New York Heart Association functional class (P < 0.05), and peak oxygen consumption (VO2 peak) (+19.3%, P < 0.01), and in a significant reduction in NT‐proBNP levels (−35.1%, P < 0.01). Notably, one additional year of combined GH and T replacement therapy induced a further increase in VO2 peak (+27.7%, final delta change + 52.44%, P < 0.01), as well as a significant improvement in muscular strength, as assessed by handgrip dynamometry (+17.5%, final delta change + 25.8%, P < 0.01). These beneficial effects were paralleled with an improvement of the overall clinical status (as assessed by New York Heart Association class). Of note, neither adverse effects nor cardiovascular events were reported during the follow‐up period.ConclusionsOur preliminary data suggest for the first time that combined replacement therapy with GH and T could be considered safe and therapeutic in HF patients with multiple hormone deficiencies, supporting the hypothesis that multiple hormone deficiencies syndrome can be considered as a novel and promising therapeutic target in HF. Further studies with a more robust design and larger population are needed.
Highlights
Preliminary clinical trials of single hormone replacement therapy to treat growth hormone deficiency (GHD)[7,8,9] or testosterone deficiency (TD)[10,11,12] have reported promising results, showing both safety and effectiveness in Notably, multiple hormone deficiencies (MHD) syndrome affects at least one third of the heart failure (HF) population,[2,4,5] no data are available so far dwelling upon combined GH and T treatment in HF patients
One-year of GH treatment resulted in a significant increase in left ventricular (LV) ejection fraction (EF) of 5.4% and in VO2 peak of 19.3%, paralleled by a non-significant trend in decreasing VE/VCO2 slope (Table 2)
The current hypothesis generating pilot study suggests that combined hormone replacement therapy yields overall beneficial effects on a wide array of cardiovascular parameters
Summary
MHD syndrome affects at least one third of the HF population,[2,4,5] no data are available so far dwelling upon combined GH and T treatment in HF patients. This information is of great relevance because both GH and T are endowed with potential adverse effects
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have